i have had new investors ask pretty basic questions in stocks that I follow closely, and more than happy to share my knowledge or views … I took one of your large investors response as rather rude and promptly returned the favour.
in terms of basic research, it’s not that hard and one of your others investors pointed directly to it.
now if it takes 5-6 years that will be around , ATH burns though approx $20m a year, so add on $75-100m and we are talking $175m-$220m total cost to get a phase 3 completed and filed.
as I said above, I hope they get a AA pathway recommended by the FDA, and if that were to happen that that is when I believe a partner will sign up. Why sign up to something (for both parties) if you don’t even know what is required to approval… quite a difference between AA and full approval when it comes to capital commitment and timeframes.
in terms of my question to this forum, I was hoping to get some discussion going as I clearly am not yet across the history of this treatment… the companies response of “we need more analysis… could be dose limiting… could also be due to the patient population rather than the treatment” doesn’t really help. Personally I would look at it as very valuable information… any data is useful from a clinical trial, trying to tick all the boxes in your first go is unrealistic and a rarity. Unexpected data can reveal limitations of your treatment, and that IMO should be used to refine any further trials, such as any potential phase 3 or confirmatory trial if they get AA. So if it turns out that certain patient populations don’t respond well.. then exclude them in the future trial.
anyway goodluck and hope to be a holder one day
(20min delay)